es, some patients may be able to switch from Mounjaro to Foundayo, but this is not a direct like-for-like conversion.
Mounjaro contains tirzepatide and acts on both GIP and GLP-1 receptors. Foundayo contains orforglipron and acts on the GLP-1 receptor. Mounjaro is injected weekly, whereas Foundayo is taken as a tablet once daily.
Mounjaro to Foundayo switching guide
| Current Mounjaro dose | Estimated Foundayo switching dose |
| 2.5 mg once weekly | 0.8 mg once daily |
| 5 mg once weekly | 2.5 mg once daily |
| 7.5 mg once weekly | 5.5 mg once daily |
| 10 mg once weekly | 9 mg once daily |
| 12.5 mg once weekly | 9 mg once daily |
| 15 mg once weekly | 9 mg once daily |
This table is Lotus's estimated switching guide. There is no clinically proven dose-for-dose conversion between Mounjaro and Foundayo, and starting Foundayo above its usual 0.8 mg starting dose is an off-label switching approach that has not been formally evaluated in a direct clinical trial.
Your prescriber may recommend a lower dose if you have experienced side effects or had a break in treatment. Mounjaro and Foundayo must not overlap; your prescriber will confirm when to take your final injection and when to begin Foundayo.
New customers can complete our online consultation. Existing Lotus customers can log in to their account, select Re-order and choose the option to change medication.